Search

Your search keyword '"Edamura, Kohei"' showing total 143 results
Start Over Author "Edamura, Kohei" Publication Year Range Last 10 years
143 results on '"Edamura, Kohei"'

1. Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement

Author

Tanegashima, Tokiyoshi, Shiota, Masaki, Kimura, Takahiro, Takamatsu, Dai, Matsui, Yoshiyuki, Yokomizo, Akira, Saito, Ryoichi, Morizane, Shuichi, Miyake, Makito, Tsutsumi, Masakazu, Yamamoto, Yoshiyuki, Tashiro, Kojiro, Tomida, Ryotaro, Edamura, Kohei, Narita, Shintaro, Yamaguchi, Takahiro, Kasahara, Takashi, Hashimoto, Kohei, Kato, Masashi, Yoshino, Takayuki, Akamatsu, Shusuke, Matsukawa, Akihiro, Kaneko, Tomoyuki, Matsumoto, Ryuji, Joraku, Akira, Kato, Manabu, Saito, Toshihiro, Kato, Takuma, Tatarano, Shuichi, Sakamoto, Shinichi, Kanno, Hidenori, Terada, Naoki, Nishiyama, Naotaka, Kitamura, Hiroshi, and Eto, Masatoshi

Published
2024
Full Text
View/download PDF

2. Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy

Author

Shiota, Masaki, Takamatsu, Dai, Matsui, Yoshiyuki, Yokomizo, Akira, Morizane, Shuichi, Saito, Ryoichi, Miyake, Makito, Tsutsumi, Masakazu, Yamamoto, Yoshiyuki, Tashiro, Kojiro, Tomida, Ryotaro, Narita, Shintaro, Edamura, Kohei, Yamaguchi, Takahiro, Hashimoto, Kohei, Kato, Masashi, Kasahara, Takashi, Yoshino, Takayuki, Akamatsu, Shusuke, Kaneko, Tomoyuki, Matsukawa, Akihiro, Matsumoto, Ryuji, Joraku, Akira, Saito, Toshihiro, Kato, Takuma, Kato, Manabu, Enokida, Hideki, Sakamoto, Shinichi, Terada, Naoki, Kanno, Hidenori, Nishiyama, Naotaka, Kimura, Takahiro, Kitamura, Hiroshi, and Eto, Masatoshi

Published
2024
Full Text
View/download PDF

3. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab

Author

Sekito, Takanori, Bekku, Kensuke, Katayama, Satoshi, Watanabe, Tomofumi, Tsuboi, Ichiro, Yoshinaga, Kasumi, Maruyama, Yuki, Yamanoi, Tomoaki, Kawada, Tatsushi, Tominaga, Yusuke, Sadahira, Takuya, Iwata, Takehiro, Nishimura, Shingo, Kusumi, Norihiro, Edamura, Kohei, Kobayashi, Tomoko, Kurose, Kyohei, Ichikawa, Takaharu, Miyaji, Yoshiyuki, Wada, Koichiro, Kobayashi, Yasuyuki, and Araki, Motoo

Published
2024
Full Text
View/download PDF

5. What is the identity of Gerota fascia? Histological study with cadavers.

Author

Kobayashi, Yasuyuki, Edamura, Kohei, Sadahira, Takuya, Tominaga, Yusuke, Katayama, Satoshi, Iwata, Takehiro, Nishimura, Shingo, Kobayashi, Tomoko, Sato, Keita, Komiyama, Takaaki, Momota, Ryusuke, Ohuchi, Hideyo, and Araki, Motoo

Subjects
*RECTUS abdominis muscles, *CONNECTIVE tissues, *LAPAROSCOPIC surgery, *COLLAGEN, *MEDICAL cadavers
Abstract

Objectives Methods Results Conclusions The advancement of laparoscopic surgery has allowed surgeons to see finer anatomical structures during surgery. As a result, several issues have arisen regarding Gerota fascia that cannot be explained by previous interpretations, such as its various forms observed during surgery. To address these issues, we histologically examined the structure of Gerota fascia.Specimens for study were prepared from kidneys with Gerota fascia from four cadavers, and the structure was studied histologically. Its thickness and collagen fiber area ratios were measured using ImageJ and compared to those of the epimysium of the rectus abdominis muscle.Connective tissue that appeared to be Gerota fascia was observed in 26 specimens. Histologically, the basic structure of Gerota fascia was a sandwich‐like structure with a thin layer of thick, long collagen fibers in the central layer, and small granular collagen fibers scattered at the edges. However, not all areas observed had a similar structure; eight specimens were composed only of small granular collagen fibers. The average thickness of the Gerota fascia was 466 μm, and the area ratio of collagen was 27.1%. In contrast, the epimysium was much thicker than Gerota fascia, and its collagen fibers were much thicker and denser.Gerota fascia, unlike the epimysium, was a very thin and fragile layer of collagen fibers, and its structure was diverse. This explains why Gerota fascia was observed in various states during surgery. It is important for surgeons to understand the properties of Gerota fascia and to treat it appropriately. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab

Author

Katayama, Satoshi, Iwata, Takehiro, Kawada, Tasushi, Okamoto, Yusuke, Sano, Yuho, Kawago, Yuya, Miyake, Shuji, Moriwake, Takatoshi, Kuinose, Aya, Horikawa, Yuhei, Tsuboi, Kazuma, Tsuboi, Ichiro, Sakaeda, Kazuma, Nakatsuka, Hirokazu, Takamoto, Atsushi, Hirata, Takeshi, Shirasaki, Yoshinori, Yamasaki, Taku, Morinaka, Hirofumi, Nagasaki, Naoya, Hara, Takafumi, Ochi, Akinori, Okumura, Misa, Watanabe, Tomofumi, Sekito, Takanori, Kawano, Kaoru, Horii, Satoshi, Yamanoi, Tomoaki, Nagao, Kentaro, Yoshinaga, Kasumi, Maruyama, Yuki, Tominaga, Yusuke, Sadahira, Takuya, Nishimura, Shingo, Edamura, Kohei, Kobayashi, Tomoko, Kusumi, Norihiro, Kurose, Kyohei, Yamamoto, Yasuo, Sugimoto, Morito, Nakada, Tetsuya, Sasaki, Katsumi, Takenaka, Tadasu, Ebara, Shin, Miyaji, Yoshiyuki, Wada, Koichiro, Kobayashi, Yasuyuki, and Araki, Motoo

Published
2024
Full Text
View/download PDF

9. Trans men can achieve adequate muscular development through low‐dose testosterone therapy: A long‐term study on body composition changes

Author

Tominaga, Yusuke, primary, Kobayashi, Tomoko, additional, Matsumoto, Yuko, additional, Moriwake, Takatoshi, additional, Oshima, Yoshitaka, additional, Okumura, Misa, additional, Horii, Satoshi, additional, Sadahira, Takuya, additional, Katayama, Satoshi, additional, Iwata, Takehiro, additional, Nishimura, Shingo, additional, Bekku, Kensuke, additional, Edamura, Kohei, additional, Sugimoto, Morito, additional, Kobayashi, Yasuyuki, additional, Watanabe, Masami, additional, Namba, Yuzaburo, additional, Matsumoto, Yosuke, additional, Nakatsuka, Mikiya, additional, and Araki, Motoo, additional

Published
2024
Full Text
View/download PDF

11. Current status and future perspectives on robot‐assisted kidney autotransplantation: A literature review.

Author

Sekito, Takanori, Yamanoi, Tomoaki, Sadahira, Takuya, Yoshinaga, Kasumi, Maruyama, Yuki, Tominaga, Yusuke, Katayama, Satoshi, Iwata, Takehiro, Nishimura, Shingo, Bekku, Kensuke, Edamura, Kohei, Kobayashi, Tomoko, Kobayashi, Yasuyuki, and Araki, Motoo

Subjects
MINIMALLY invasive procedures, LITERATURE reviews, UROLOGICAL surgery, NEPHRECTOMY, AUTOTRANSPLANTATION, SURGICAL robots, KIDNEY transplantation
Abstract

This review presents the latest insights on robot‐assisted kidney autotransplantation (RAKAT). RAKAT is a minimally invasive surgical procedure and represents a promising alternative to conventional laparoscopic nephrectomy followed by open kidney transplantation for the treatment of various complex urological and vascular conditions. RAKAT can be performed either extracorporeally or intracorporeally. Additionally, a single‐port approach can be performed through one small incision without the need to reposition the patient. Of 86 patients undergoing RAKAT, 8 (9.3%) developed postoperative > Grade 2 Clavien‐Dindo (CD) complications. Although the feasibility of RAKAT was established in 2014, the long‐term efficacy and safety along with outcomes of this surgical approach are still being evaluated, and additional studies are needed. With improvements in the technology of RAKAT and as surgeons gain more experience, RAKAT should become increasingly used and further refined, thereby leading to improved surgical outcomes and improved patients' quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab

Author

Katayama, Satoshi, primary, Iwata, Takehiro, additional, Kawada, Tasushi, additional, Okamoto, Yusuke, additional, Sano, Yuho, additional, Kawago, Yuya, additional, Miyake, Shuji, additional, Moriwake, Takatoshi, additional, Kuinose, Aya, additional, Horikawa, Yuhei, additional, Tsuboi, Kazuma, additional, Tsuboi, Ichiro, additional, Sakaeda, Kazuma, additional, Nakatsuka, Hirokazu, additional, Takamoto, Atsushi, additional, Hirata, Takeshi, additional, Shirasaki, Yoshinori, additional, Yamasaki, Taku, additional, Morinaka, Hirofumi, additional, Nagasaki, Naoya, additional, Hara, Takafumi, additional, Ochi, Akinori, additional, Okumura, Misa, additional, Watanabe, Tomofumi, additional, Sekito, Takanori, additional, Kawano, Kaoru, additional, Horii, Satoshi, additional, Yamanoi, Tomoaki, additional, Nagao, Kentaro, additional, Yoshinaga, Kasumi, additional, Maruyama, Yuki, additional, Tominaga, Yusuke, additional, Sadahira, Takuya, additional, Nishimura, Shingo, additional, Edamura, Kohei, additional, Kobayashi, Tomoko, additional, Kusumi, Norihiro, additional, Kurose, Kyohei, additional, Yamamoto, Yasuo, additional, Sugimoto, Morito, additional, Nakada, Tetsuya, additional, Sasaki, Katsumi, additional, Takenaka, Tadasu, additional, Ebara, Shin, additional, Miyaji, Yoshiyuki, additional, Wada, Koichiro, additional, Kobayashi, Yasuyuki, additional, and Araki, Motoo, additional

Published
2023
Full Text
View/download PDF

13. Photodynamic diagnostic ureteroscopy using the VISERA ELITE video system for diagnosis of upper-urinary tract urothelial carcinoma: a prospective cohort pilot study

Author

Wada, Koichiro, Araki, Motoo, Tanimoto, Ryuta, Sadahira, Takuya, Watari, Shogo, Maruyama, Yuki, Mitsui, Yosuke, Nakajima, Hirochika, Acosta, Herik, Katayama, Satoshi, Iwata, Takehiro, Nishimura, Shingo, Takamoto, Atsushi, Sako, Tomoko, Edamura, Kohei, Kobayashi, Yasuyuki, Watanabe, Masami, Watanabe, Toyohiko, and Nasu, Yasutomo

Published
2021
Full Text
View/download PDF

14. The Diagnosis and Treatment Approach for Oligo-Recurrent and Oligo-Progressive Renal Cell Carcinoma.

Author

Bekku, Kensuke, Kawada, Tatsushi, Sekito, Takanori, Yoshinaga, Kasumi, Maruyama, Yuki, Yamanoi, Tomoaki, Tominaga, Yusuke, Sadahira, Takuya, Katayama, Satoshi, Iwata, Takehiro, Nishimura, Shingo, Edamura, Kohei, Kobayashi, Tomoko, Kobayashi, Yasuyuki, Araki, Motoo, and Niibe, Yuzuru

Subjects
RENAL cell carcinoma, DISEASE progression, IMMUNE checkpoint inhibitors, METASTASIS, CANCER relapse, METASTASECTOMY
Abstract

Simple Summary: Oligo-recurrence and oligo-progression in oncology refer to scenarios in which five or fewer metastases develop after the primary lesions and other metastases have been treated using radical surgery or controlled using systemic therapy. Such scenarios are now considered favorable indications for metastasis-directed treatment (MDT), where a curative approach is possible. The primary strategy for recurrence and metastases in renal cell carcinoma (RCC) is systemic therapy, which includes immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor tyrosine kinase inhibitors. However, MDTs such as stereotactic body radiation therapy, which involves larger doses administered over fewer fractions than conventional radiation therapy, have shown the potential to improve outcomes for selected patients with RCC experiencing oligo-recurrence and oligo-progression. Combining MDT with ICIs may yield better results owing to their synergistic effects. In this review, we provide an overview of the current evidence related to the management of oligo-recurrent and -progressive RCC. One-third of renal cell carcinomas (RCCs) without metastases develop metastatic disease after extirpative surgery for the primary tumors. The majority of metastatic RCC cases, along with treated primary lesions, involve limited lesions termed "oligo-recurrent" disease. The role of metastasis-directed therapy (MDT), including stereotactic body radiation therapy (SBRT) and metastasectomy, in the treatment of oligo-recurrent RCC has evolved. Although the surgical resection of all lesions alone can have a curative intent, SBRT is a valuable treatment option, especially for patients concurrently receiving systemic therapy. Contemporary immune checkpoint inhibitor (ICI) combination therapies remain central to the management of metastatic RCC. However, one objective of MDT is to delay the initiation of systemic therapies, thereby sparing patients from potentially unnecessary burdens. Undertaking MDT for cases showing progression under systemic therapies, known as "oligo-progression", can be complex in considering the treatment approach. Its efficacy may be diminished compared to patients with stable disease. SBRT combined with ICI can be a promising treatment for these cases because radiation therapy has been shown to affect the tumor microenvironment and areas beyond the irradiated sites. This may enhance the efficacy of ICIs, although their efficacy has only been demonstrated in clinical trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Data from Functional Analysis of Secreted Caveolin-1 in Mouse Models of Prostate Cancer Progression

Author

Watanabe, Masami, primary, Yang, Guang, primary, Cao, Guangwen, primary, Tahir, Salahaldin A., primary, Naruishi, Koji, primary, Tabata, Ken-ichi, primary, Fattah, Elmoataz Abdel, primary, Rajagopalan, Kartik, primary, Timme, Terry L., primary, Park, Sanghee, primary, Kurosaka, Shinji, primary, Edamura, Kohei, primary, Tanimoto, Ryuta, primary, Demayo, Francesco J., primary, Goltsov, Alexei A., primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Methods from Caveolin-1 Upregulation Contributes to c-Myc–Induced High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer

Author

Yang, Guang, primary, Goltsov, Alexei A., primary, Ren, Chengzhen, primary, Kurosaka, Shinji, primary, Edamura, Kohei, primary, Logothetis, Richard, primary, DeMayo, Francesco J., primary, Troncoso, Patricia, primary, Blando, Jorge, primary, DiGiovanni, John, primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from Functional Analysis of Secreted Caveolin-1 in Mouse Models of Prostate Cancer Progression

Author

Watanabe, Masami, primary, Yang, Guang, primary, Cao, Guangwen, primary, Tahir, Salahaldin A., primary, Naruishi, Koji, primary, Tabata, Ken-ichi, primary, Fattah, Elmoataz Abdel, primary, Rajagopalan, Kartik, primary, Timme, Terry L., primary, Park, Sanghee, primary, Kurosaka, Shinji, primary, Edamura, Kohei, primary, Tanimoto, Ryuta, primary, Demayo, Francesco J., primary, Goltsov, Alexei A., primary, and Thompson, Timothy C., primary

Published
2023
Full Text
View/download PDF

20. MP31-17 LOW-DOSE RITUXIMAB INDUCTION THERAPY IN IMMUNOLOGIC HIGH-RISK RENAL TRANSPLANTATION PROVIDES FAVORABLE GRAFT OUTCOMES WITHOUT INCREASING CYTOMEGALOVIRUS INFECTION: A 5-YEAR FOLLOW-UP

Author

Yoshinaga, Kasumi, primary, Maruyama, Yuki, additional, Yamanoi, Tomoaki, additional, Nishimura, Shingo, additional, Tominaga, Yusuke, additional, Katayama, Satoshi, additional, Iwata, Takehiro, additional, Edamura, Kohei, additional, Kobayashi, Tomoko, additional, Kobayashi, Yasuyuki, additional, Watanabe, Toyohiko, additional, and Araki, Motoo, additional

Published
2023
Full Text
View/download PDF

21. Bladder tuberculosis with ureteral strictures after bacillus Calmette‑Guérin therapy for urinary bladder cancer: A case report

Author

Tominaga, Yusuke, primary, Fujii, Masanori, additional, Sadahira, Takuya, additional, Katayama, Satoshi, additional, Iwata, Takehiro, additional, Nishimura, Shingo, additional, Bekku, Kensuke, additional, Edamura, Kohei, additional, Kobayashi, Tomoko, additional, Kobayashi, Yasuyuki, additional, Kiura, Katsuyuki, additional, Maeda, Yoshinobu, additional, Wada, Koichiro, additional, and Araki, Motoo, additional

Published
2022
Full Text
View/download PDF

22. Management of patients with advanced prostate cancer in Japan: ‘real-world’ consideration of the results from the Advanced Prostate Cancer Consensus Conference

Author

Fujita, Kazutoshi, primary, Suzuki, Hiroyoshi, additional, Hinata, Nobuyuki, additional, Miura, Yuji, additional, Edamura, Kohei, additional, Tabata, Ken-Ichi, additional, Arai, Gaku, additional, Matsubara, Nobuaki, additional, Yasumizu, Yota, additional, Kosaka, Takeo, additional, Oya, Mototsugu, additional, and Sugimoto, Mikio, additional

Published
2022
Full Text
View/download PDF

27. Simplified PADUA REnal (SPARE) Nephrometry System can Describe the Surgical Difficulty of Renal Masses With High Accuracy Even Without 3D Renal Models

Author

Watanabe, Tomofumi, Sadahira, Takuya, Sekito, Takanori, Maruyama, Yuki, Edamura, Kohei, Kobayashi, Yasuyuki, Araki, Motoo, Watanabe, Tomofumi, Sadahira, Takuya, Sekito, Takanori, Maruyama, Yuki, Edamura, Kohei, Kobayashi, Yasuyuki, and Araki, Motoo

Abstract

Objective: To evaluate whether a 2-dimensional(2D) model describes the surgical difficulty of a renal mass accurately comparable to that obtained using a 3D model with the Simplified PADUA REnal nephrometry system (SPARE). Methods: A total of 100 patients underwent RAPN in our hospital between October 2018 and May 2021. We excluded patients with CT images inappropriate for evaluation or for construction of 3D models, patients with multiple tumors, and those who underwent preoperative transcatheter arterial embolization. We conducted a retrospective analysis of the remaining patients using SPARE predictions from CT images (2D-SPARE) and SPARE predictions from 3D models (3D-SPARE). We evaluated the difference between the 2 nephrometry scores and compared them by their ability to predict the achievement of the desired surgical outcome: absence of positive margins, absence of ischemia, and absence of significant complications. Results: A total of 87 patients were included in this study. Total score, and risk categorization using 3D-SPARE was significantly different from those using 2D-SPARE (P <.05), but in their areas under the curve (AUC), the scores and categorizations were not significantly different (score, 0.763 vs 0.742; P = .501; categorization, 0.711 vs 0.701; P = .755). Conclusion: The SPARE system can describe the surgical difficulty of renal masses with high accuracy even without the use of 3D renal models.

Published
2022

28. Bladder tuberculosis with ureteral strictures after bacillus Calmette‑Guérin therapy for urinary bladder cancer: A case report

Author

Tominaga, Yusuke, Fujii, Masanori, Sadahira, Takuya, Katayama, Satoshi, Iwata, Takehiro, Nishimura, Shingo, Bekku, Kensuke, Edamura, Kohei, Kobayashi, Tomoko, Kobayashi, Yasuyuki, Kiura, Katsuyuki, Maeda, Yoshinobu, Wada, Koichiro, Araki, Motoo, Tominaga, Yusuke, Fujii, Masanori, Sadahira, Takuya, Katayama, Satoshi, Iwata, Takehiro, Nishimura, Shingo, Bekku, Kensuke, Edamura, Kohei, Kobayashi, Tomoko, Kobayashi, Yasuyuki, Kiura, Katsuyuki, Maeda, Yoshinobu, Wada, Koichiro, and Araki, Motoo

Abstract

Intravesical immunotherapy using bacillus Calmette‑Guérin (BCG) is recommended for patients with intermediate‑ to high‑risk non‑muscle invasive bladder cancer. Bladder tuberculosis (TB) is a rare complication of BCG therapy. The present study describes the case of a 73‑year‑old man who underwent intravesical BCG therapy for urothelial carcinoma in situ of the bladder. Red patches around the resection scar were first detected 1 year and 5 months after BCG treatment; these findings gradually spread to encompass more of the bladder wall. Transurethral biopsy revealed a benign lesion, but the patient developed bilateral hydronephrosis and mild voiding dysfunction. The patient was eventually diagnosed with bladder TB by mycobacterial urine culture and TB‑specific polymerase chain reaction (PCR). The patient was given multidrug therapy (isoniazid, rifampicin and ethambutol) and their bladder TB was completely cured; however, their voiding dysfunction and bilateral hydronephrosis did not fully improve. Bladder TB can occur long after intravesical BCG administration and cystoscopy findings consistent with inflammation can be the key to suspecting this condition. Acid‑fast examination and PCR testing of a urine sample are necessary for early diagnosis.

Published
2022

29. Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial

Author

Sadahira, Takuya, Wada, Koichiro, Araki, Motoo, Ishii, Ayano, Takamoto, Atsushi, Kobayashi, Yasuyuki, Watanabe, Masami, Watanabe, Toyohiko, Nasu, Yasutomo, Kumon, Hiromi, Nasu, Yasutomo, Akaeda, Teruaki, Akazawa, Nobuyuki, Akebi, Naoki, Araki, Daiji, Araki, Tohru, Araki, Motoo, Arata, Ryoji, Ariyoshi, Yuichi, Ando, Eiichi, Ando, Nobuyoshi, Ishii, Ayano, Ishii, Kazushi, Ishikawa, Tsutomu, Ishito, Noritaka, Ichikawa, Takaharu, Inoue, Takaaki, Inoue, Miyabi, Inoue, Yosuke, Irie, Shin, Iwata, Takehiro, Uesugi, Tatsuya, Uehara, Shinya, Uematsu, Katsutoshi, Uno, Satoshi, Edamura, Kohei, Ebara, Shin, Oiwa, Yuko, Oeda, Tadashi, Ohashi, Teruhisa, Ohashi, Yozo, Ozawa, Hideo, Ochi, Junzo, Ono, Noriaki, Kai, Seiji, Kaku, Haruki, Katayama, Satoshi, Katayama, Yasuhiro, Kaneshige, Tetuzo, Kawauchi, Keiichiro, Kawaguchi, Masashi, Kawada, Tatsushi, Kanbara, Taiki, Kishi, Mikio, Kishimoto, Ryo, Kusaka, Nobuyuki, Kusumi, Norihiro, Kunitomi, Kimito, Kubota, Risa, Kumon, Hiromi, Kurahashi, Hiroaki, Kojima, Hironori, Kobayashi, Tomoko, Kobayashi, Yasuyuki, Kobuke, Makoto, Kondo, Katsuyoshi, Saika, Takashi, Sakaeda, Kazuma, Sakuramoto, Koji, Sako, Shinichi, Sako, Tomoko, Sasaoka, Taketo, Sasaki, Katsumi, Sadahira, Takuya, Jo, Yoshimasa, Sugimoto, Morito, Seno, Yuko, Takao, Akira, Takamura, Kosuke, Takamura, Kousuke, Takamoto, Atsushi, Takamoto, Hitoshi, Takeda, Katsuji, Takenaka, Tadasu, Tanaka, Daisuke, Tanimoto, Ryuta, Tsugawa, Masaya, Tsushima, Tomoyasu, Tsuboi, Hiromu, Tojo, Syunji, Tokinaga, Kenji, Tominaga, Yusuke, Doi, Keisuke, Nagai, Atsushi, Nakajima, Hirochika, Nakada, Tetsuya, Nakatsuka, Hirokazu, Nakamura, Aya, Nakayama, Yasuki, Nasu, Yoshitsugu, Nishikawa, Daisuke, Nishiguchi, Jun, Nishitani, Yoshio, Nishimura, Shingo, Nishimura, Motoichi, Nishiyama, Yasuhiro, Nibuno, Hajime, Nozaki, Kunihiro, Nose, Hiroyuki, Noda, Gaku, Hashimoto, Hideaki, Hata, Kazuhiro, Hayashi, Toshihide, Hayashi, Nobuki, Hayata, Syunji, Hara, Ryoei, Hirata, Takeshi, Fujii, Tomohiro, Fujio, Kei, Fujita, Ryuji, Bekku, Kensuke, Maehara, Takanori, Maki, Yoshio, Matsumoto, Yuko, Manabe, Daisuke, Mayumi, Yusuke, Maruyama, Yuki, Mitsui, Yosuke, Miyaji, Sadayuki, Munemasa, Syuhei, Murao, Wataru, Murakami, Takanori, Murata, Tadashi, Mori, Akihiro, Morita, Akira, Monden, Koichi, Yamasaki, Tomoya, Yamashita, Masahiro, Yamada, Daiduke, Yamato, Toyoko, Yamane, Toru, Yamanoi, Tomoaki, Yamamoto, Yasuo, Yukari, Kazuaki, Yokoyama, Teruhiko, Yoshioka, Takashi, Watanabe, Toyohiko, Watanabe, Masami, Watanabe, Yuichi, and Wada, Koichiro

Published
2017
Full Text
View/download PDF

31. A Novel Technique Using Fluorescent Ureteral Catheter and Flexible Ureteroscope for Safe Laparoscopic Fenestration of Lymphocele after Kidney Transplantation

Author

Sekito, Takanori, Araki, Motoo, Wada, Koichiro, Yoshinaga, Kasumi, Maruyama, Yuki, Sadahira, Takuya, Katayama, Satoshi, Iwata, Takehiro, Nishimura, Shingo, Sako, Tomoko, Edamura, Kohei, Kobayashi, Yasuyuki, and Watanabe, Toyohiko

Subjects
surgical procedures, operative, Article Subject, urologic and male genital diseases
Abstract

Laparoscopic fenestration of a postrenal transplant lymphocele is associated with a risk of renal hilar vessel and ureteral injury. Consequently, determination of the incision line is difficult. We describe a case of a 73-year-old man with postrenal transplant lymphocele who underwent a laparoscopic fenestration. We report a surgical video containing a new technique of laparoscopic fenestration using a fluorescent ureteral catheter in combination with a flexible ureteroscope. The combination of a fluorescent ureteral catheter and flexible ureteroscope during surgery enabled us to determine the incision line safely and accurately. Intraoperative real-time visualization of the lymphocele and ureter using a fluorescent ureteral catheter and a flexible ureteroscope is safer than conventional methods for laparoscopic fenestration. To the best of our knowledge, this is the first report of this novel technique.

Published
2022
Full Text
View/download PDF

32. Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections

Author

Iwata, Takehiro, Sadahira, Takuya, Maruyama, Yuki, Sekito, Takanori, Yoshinaga, Kasumi, Watari, Shogo, Nagao, Kentaro, Kawada, Tatsushi, Tominaga, Yusuke, Nishimura, Shingo, Takamoto, Atsushi, Sako, Tomoko, Edamura, Kohei, Kobayashi, Yasuyuki, Araki, Motoo, Ishii, Ayano, Watanabe, Masami, Watanabe, Toyohiko, Nasu, Yasutomo, and Wada, Koichiro

Subjects
Adult, fluoroquinolone resistance, Treatment Outcome, Urinary Tract Infections, extended-spectrum beta-lactamase, Humans, Bacterial Infections, genitourinary tract infections, Anti-Bacterial Agents, Fluoroquinolones
Abstract

The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.

Published
2021

33. Medical uses for silver nitrate in the urinary tract (Review)

Author

Sekito, Takanori, primary, Sadahira, Takuya, additional, Watanabe, Toyohiko, additional, Maruyama, Yuki, additional, Watanabe, Tomofumi, additional, Iwata, Takehiro, additional, Wada, Koichiro, additional, Edamura, Kohei, additional, Araki, Motoo, additional, and Watanabe, Masami, additional

Published
2022
Full Text
View/download PDF

34. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab

Author

Sekito, Takanori, Takamoto, Atsushi, Kobayashi, Yasuyuki, Mitsui, Masao, Watari, Shogo, Kubota, Risa, Sadahira, Takuya, Iwata, Takehiro, Nishimura, Shingo, Edamura, Kohei, Sako, Tomoko, Araki, Motoo, Watanabe, Masami, Watanabe, Toyohiko, Shibata, Rei, Ennishi, Daisuke, and Nasu, Yasutomo

Subjects
Male, renal cell carcinoma, Middle Aged, urologic and male genital diseases, Ipilimumab, Nephrectomy, female genital diseases and pregnancy complications, Kidney Neoplasms, Fumarate Hydratase, Antineoplastic Agents, Immunological, Nivolumab, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Humans, fumarate hydratase-deficient renal cell carcinoma, Tomography, X-Ray Computed, neoplasms, Carcinoma, Renal Cell, Germ-Line Mutation
Abstract

We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) without fumarate hydratase (FH) mutation (FH-deficient–like RCC). The International Metastatic RCC Database Consortium risk score was intermediate, and immunotherapy with nivolumab and ipilimumab (Ipi/ Nivo) was initiated. Four cycles of Ipi/Nivo and 5 cycles of nivolumab resulted in a complete response of the metastases. Hypophysitis occurred as an immune-related adverse event after four cycles of Ipi/Nivo. The prognosis of patients with FH-deficient RCC is generally poor. Few reports of FH-deficient RCC successfully treated with Ipi/Nivo have been published. Ipi/Nivo can be effective for treating FH-deficient RCC.

Published
2021

35. MP37-09 THE NOVEL IN VIVO REAL-TIME IMAGING TECHNIQUES VISUALIZE THE NEUTROPHIL INFILTRATION FOLLOWING RENAL ISCHEMIA/REPERFUSION

Author

Maruyama, Yuki, primary, Araki, Moto, additional, Kidokoro, Kengo, additional, Yoshinaga, Kasumi, additional, Mitsui, Yosuke, additional, Sadahira, Takuya, additional, Nishimura, Shingo, additional, Wada, Koichiro, additional, Edamura, Kohei, additional, Kobayashi, Yasuyuki, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, Kashihara, Naoki, additional, and Nasu, Yasutomo, additional

Published
2021
Full Text
View/download PDF

36. MP37-15 DETECTION OF DECOY CELLS IN SIX MONTHS OR MORE ON URINARY CYTOLOGY EFFICIENTLY AND COST-EFFECTIVELY PREDICTS BK VIRUS NEPHROPATHY IN RENAL TRANSPLANT RECIPIENTS

Author

Sekito, Takanori, primary, Araki, Motoo, additional, Yoshinaga, Kasumi, additional, Watari, Syogo, additional, Maruyama, Yuki, additional, Sadahira, Takuya, additional, Nishimura, Shingo, additional, Wada, Koichiro, additional, Sako, Tomoko, additional, Edamura, Kohei, additional, Kobayashi, Yasuyuki, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, Yanai, Hiroyuki, additional, and Nasu, Yasutomo, additional

Published
2021
Full Text
View/download PDF

38. Successful deceased donor kidney transplantation to a recipient with a history of COVID-19 treatment

Author

Yoshinaga, Kasumi, primary, Araki, Motoo, additional, Wada, Koichiro, additional, Hasegawa, Kou, additional, Sekito, Takanori, additional, Miyake, Shuji, additional, Watari, Shogo, additional, Maruyama, Yuki, additional, Sadahira, Takuya, additional, Nishimura, Shingo, additional, Tanabe, Katsuyuki, additional, Takeuchi, Hidemi, additional, Nakashima, Yuri, additional, Kinomura, Masaru, additional, Acosta, Herik, additional, Mitsui, Yosuke, additional, Kubota, Risa, additional, Nakajima, Hirochika, additional, Edamura, Kohei, additional, Kobayashi, Yasuyuki, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, Otsuka, Fumio, additional, Wada, Jun, additional, and Nasu, Yasutomo, additional

Published
2021
Full Text
View/download PDF

39. Feasible kidney donation with living marginal donors, including diabetes mellitus

Author

Yoshinaga, Kasumi, primary, Araki, Motoo, additional, Wada, Koichiro, additional, Sekito, Takanori, additional, Watari, Shogo, additional, Maruyama, Yuki, additional, Mitsui, Yosuke, additional, Sadahira, Takuya, additional, Kubota, Risa, additional, Nishimura, Shingo, additional, Edamura, Kohei, additional, Kobayashi, Yasuyuki, additional, Tanabe, Katsuyuki, additional, Takeuchi, Hidemi, additional, Kitagawa, Masashi, additional, Kitamura, Shinji, additional, Wada, Jun, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, and Nasu, Yasutomo, additional

Published
2021
Full Text
View/download PDF

40. Feasible kidney donation with living marginal donors, including diabetes mellitus

Author

Yoshinaga, Kasumi, Araki, Motoo, Wada, Koichiro, Sekito, Takanori, Watari, Shogo, Maruyama, Yuki, Mitsui, Yosuke, Sadahira, Takuya, Kubota, Risa, Nishimura, Shingo, Edamura, Kohei, Kobayashi, Yasuyuki, Tanabe, Katsuyuki, Takeuchi, Hidemi, Kitagawa, Masashi, Kitamura, Shinji, Wada, Jun, Watanabe, Masami, Watanabe, Toyohiko, Nasu, Yasutomo, Yoshinaga, Kasumi, Araki, Motoo, Wada, Koichiro, Sekito, Takanori, Watari, Shogo, Maruyama, Yuki, Mitsui, Yosuke, Sadahira, Takuya, Kubota, Risa, Nishimura, Shingo, Edamura, Kohei, Kobayashi, Yasuyuki, Tanabe, Katsuyuki, Takeuchi, Hidemi, Kitagawa, Masashi, Kitamura, Shinji, Wada, Jun, Watanabe, Masami, Watanabe, Toyohiko, and Nasu, Yasutomo

Abstract

Objectives: To compare the donor outcomes of living donor kidney transplantation between standard donors (SDs) and marginal donors (MDs) including diabetic patients (MD + DM). Methods: MDs were defined according to Japanese guideline criteria: (a) age >70-years, (b) blood pressure <= 130/80 mmHg on hypertension medicine, (c) body mass index >25 to <= 32 kg/m(2), (d) 24-h creatinine clearance >= 70 to <80 ml/min/1.73 m(2), and (e) hemoglobin A1c > 6.2 or <= 6.5 with oral diabetic medicine. Fifty-three of 114 donors were MDs. We compared donor kidney functions until 60 months postoperatively. Results: No kidney function parameters were different between SDs and MDs. When comparing SD and MD + DM, MD + DM had a lower postoperative eGFR (48 vs. 41 (1 (month), p = .02), 49 vs. 40 (12, p < .01), 48 vs. 42 (24, p = .04), 47 vs. 38 (36, p = .01)) and the percentage of residual eGFR (SD vs. MD + DM: 63 vs. 57 (1 (month), p < .01), 63 vs. 57 (2, p < .01), 64 vs. 56 (12, p < .01), 63 vs. 57 (24, p < .01), 63 vs. 52 (36, p = .02)). However, when MD with a single risk factor of DM was compared to SD, the difference disappeared. Nine out of 12 (75%) MD + DM had >= 2 risk factors. Conclusions: Although long-term observation of donor kidney function is necessary, careful MD + DM selection had the potential to expand the donor pool.

Published
2021

41. Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer.

Author

Shiota, Masaki, Takamatsu, Dai, Kimura, Takahiro, Tashiro, Kojiro, Matsui, Yoshiyuki, Tomida, Ryotaro, Saito, Ryoichi, Tsutsumi, Masakazu, Yokomizo, Akira, Yamamoto, Yoshiyuki, Edamura, Kohei, Miyake, Makito, Morizane, Shuichi, Yoshino, Takayuki, Matsukawa, Akihiro, Narita, Shintaro, Matsumoto, Ryuji, Kasahara, Takashi, Hashimoto, Kohei, and Matsumoto, Hiroaki

Abstract

The treatment for lymph node involvement (LNI) after radical prostatectomy (RP) has not been established. This study aimed to reveal the outcomes of various management strategies among patients with LNI after RP. Retrospectively, 561 patients with LNI after pelvic lymph node dissection (PLND) with RP treated between 2006 and 2019 at 33 institutions participating in the Japanese Urological Oncology Group were investigated. Metastasis‐free survival (MFS) was the primary outcome. Patients were stratified by prostate‐specific antigen (PSA) persistence after RP. Cox regression models were used to analyze the relationships between clinicopathological characteristics and survival. Survival analyses were conducted using the Kaplan‐Meier method and log‐rank test with or without propensity score matching. Prognoses, including MFS and overall survival, were prominently inferior among patients with persistent PSA compared with those without persistent PSA. In multivariate analysis, androgen deprivation therapy (ADT) plus radiotherapy (RT) was associated with better MFS than ADT alone among patients with persistent PSA (hazard ratio = 0.37; 95% confidence interval = 0.15‐0.93; p = 0.034). Similarly, MFS and overall survival were significantly better for ADT plus RT than for ADT alone among patients with persistent PSA after propensity score matching. This study indicated that PSA persistence in LNI prostate cancer increased the risk of poor prognoses, and intensive treatment featuring the addition of RT to ADT might improve survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma

Author

Katayama, Satoshi, primary, Kobayashi, Yasuyuki, additional, Takamoto, Atsushi, additional, Edamura, Kohei, additional, Sadahira, Takuya, additional, Iwata, Takehiro, additional, Nishimura, Shingo, additional, Sako, Tomoko, additional, Wada, Koichiro, additional, Araki, Motoo, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, and Nasu, Yasutomo, additional

Published
2021
Full Text
View/download PDF

43. Long-term ureteroscopic management of upper tract urothelial carcinoma: 28-year single-centre experience

Author

Maruyama, Yuki, Araki, Motoo, Wada, Koichiro, Yoshinaga, Kasumi, Mitsui, Yosuke, Sadahira, Takuya, Nishimura, Shingo, Edamura, Kohei, Kobayashi, Yasuyuki, Watanabe, Masami, Watanabe, Toyohiko, Monga, Manoj, Nasu, Yasutomo, Kumon, Hiromi, Maruyama, Yuki, Araki, Motoo, Wada, Koichiro, Yoshinaga, Kasumi, Mitsui, Yosuke, Sadahira, Takuya, Nishimura, Shingo, Edamura, Kohei, Kobayashi, Yasuyuki, Watanabe, Masami, Watanabe, Toyohiko, Monga, Manoj, Nasu, Yasutomo, and Kumon, Hiromi

Abstract

Background Long-term survival outcomes of patients who undergo endoscopic management of non-invasive upper tract urothelial carcinoma remain uncertain. The longest mean follow-up period in previous studies was 6.1 years. This study reports the long-term outcomes of patients with upper tract urothelial carcinoma who underwent ureteroscopic ablation at a single institution over a 28-year period. Methods We identified all patients who underwent ureteroscopic management of upper tract urothelial carcinoma as their primary treatment at our institution between January 1991 and April 2011. Survival outcomes, including overall survival, cancer-specific survival, upper-tract recurrence-free survival and renal unit survival, were estimated using Kaplan−Meier methodology. Results A total of 15 patients underwent endoscopic management, with a mean age at diagnosis of 66 years. All patients underwent ureteroscopy, and biopsy-confirmed pathology was obtained. Median (range; mean) follow-up was 11.7 (2.3–20.9, 11.9) years. Upper tract recurrence occurred in 87% (n = 13) of patients. Twenty percent (n = 3) of patients proceeded to nephroureterectomy. The estimated cancer-specific survival rate was 93% at 5, 10, 15 and 20 years. Estimated overall survival rates were 86, 80, 54 and 20% at 5, 10, 15 and 20 years. Only one patient experienced cancer-specific mortality. The estimated mean and median overall survival times were 14.5 and 16.6 years, respectively. The estimated mean cancer-specific survival time was not reached. Conclusions Although upper tract recurrence is common, endoscopic management of non-invasive upper tract urothelial carcinoma provides a 90% cancer-specific survival rate at 20 years in selected patients.

Published
2020

44. Photodynamic Diagnostic Ureteroscopy Using The VISERA ELITE® Video System For Diagnosis of Upper-Urinary Tract Urothelial Carcinoma: A Prospective Cohort Pilot Study

Author

Wada, Koichiro, primary, Araki, Motoo, additional, Tanimoto, Ryuta, additional, Sadahira, Takuya, additional, Watari, Shogo, additional, Maruyama, Yuki, additional, Mitsui, Yosuke, additional, Nakajima, Hirochika, additional, Acosta, Herik, additional, Katayama, Satoshi, additional, Iwata, Takehiro, additional, Nishimura, Shingo, additional, Takamoto, Atsushi, additional, Sako, Tomoko, additional, Edamura, Kohei, additional, Kobayashi, Yasuyuki, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, and Nasu, Yasutomo, additional

Published
2021
Full Text
View/download PDF

45. Long-term ureteroscopic management of upper tract urothelial carcinoma: 28-year single-centre experience

Author

Maruyama, Yuki, primary, Araki, Motoo, additional, Wada, Koichiro, additional, Yoshinaga, Kasumi, additional, Mitsui, Yosuke, additional, Sadahira, Takuya, additional, Nishimura, Shingo, additional, Edamura, Kohei, additional, Kobayashi, Yasuyuki, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, Monga, Manoj, additional, Nasu, Yasutomo, additional, and Kumon, Hiromi, additional

Published
2020
Full Text
View/download PDF

46. MP52-12 RENAL TRANSPLANTATION FROM MARGINAL DONOR; THE SAFETY AND POSSIBILITY

Author

Yoshinaga*, Kasumi, primary, Araki, Motoo, additional, Maruyama, Yuki, additional, Mitsui, Yosuke, additional, Sadahira, Takuya, additional, Sekito, Takanori, additional, Kubota, Risa, additional, Nishimura, Shingo, additional, Sako, Tomoko, additional, Edamura, Kohei, additional, Kobayashi, Yasuyuki, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, and Nasu, Yasutomo, additional

Published
2020
Full Text
View/download PDF

47. MP75-12 THE SECOND OPINION PATHOLOGY REVIEW IMPROVES CONCORDANCE BETWEEN PROSTATE BIOPSY AND RADICAL PROSTATECTOMY SPECIMENS

Author

Maruyama*, Yuki, primary, Sadahira, Takuya, additional, Araki, Motoo, additional, Mitsui, Yosuke, additional, Wada, Koichiro, additional, Rodrigo, Acosta, additional, Edamura, Kohei, additional, Kobayashi, Yasuyuki, additional, Watanabe, Masami, additional, Watanabe, Toyohiko, additional, and Nasu, Yasutomo, additional

Published
2020
Full Text
View/download PDF

48. The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma

Author

Hirata, Takeshi, Hanamoto, Masanori, Ogura, Kazuma, Hayashi, Nobuki, Takamura, Kosuke, Edamura, Kohei, Ebara, Shin, and Saika, Takashi

Subjects
second-line, Male, Salvage Therapy, Urologic Neoplasms, Paclitaxel, Deoxycytidine, Gemcitabine, Treatment Outcome, salvage, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Cisplatin, Neoplasm Recurrence, Local, urothelial carcinoma, Aged, Retrospective Studies
Abstract

There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1. The 3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity. The overall response rate was 61% (95%CI, 41-78%). The median overall survival and progression-free survival times were 14 months and 5.5 months, respectively. Of the already known risk factors of chemotherapy for advanced UC, only the performance status was a prognostic factor for OS. Overall, 16 of the 23 patients (70%) experienced grade 3/4 toxicities, and no fatal adverse events were observed. GCP therapy was a promising option as second-line or salvage therapy for advanced UC.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results